vs
Side-by-side financial comparison of FRACTYL HEALTH, INC. (GUTS) and Sigma Lithium Corp (SGML). Click either name above to swap in a different company.
Sigma Lithium Corp is the larger business by last-quarter revenue ($15.3K vs $14.0K, roughly 1.1× FRACTYL HEALTH, INC.). Sigma Lithium Corp runs the higher net margin — -120.1% vs -165521.4%, a 165401.3% gap on every dollar of revenue.
Fractyl Health is a Burlington, Massachusetts-based healthcare company focused on metabolic diseases like obesity and type 2 diabetes. The company developed Revita, an outpatient endoscopic procedure to modify duodenal dysfunction, and Rejuva, a gene therapy platform in preclinical development to enable the pancreas to produce glucagon-like peptide-1 (GLP-1).
Sigma Lithium Corp is a sustainable lithium mining firm operating assets primarily in Brazil. It produces high-purity battery-grade lithium concentrate, supplying global electric vehicle manufacturers and energy storage providers to support the global clean energy transition.
GUTS vs SGML — Head-to-Head
Income Statement — Q3 FY2024 vs Q3 FY2024
| Metric | | |
|---|---|---|
| Revenue | $14.0K | $15.3K |
| Net Profit | $-23.2M | $-25.1K |
| Gross Margin | 50.0% | — |
| Operating Margin | -169957.1% | — |
| Net Margin | -165521.4% | -120.1% |
| Revenue YoY | — | — |
| Net Profit YoY | — | — |
| EPS (diluted) | $-0.48 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 24 | $14.0K | $15.3K | ||
| Q2 24 | $43.0K | $33.5K | ||
| Q1 24 | $33.0K | — |
| Q3 24 | $-23.2M | $-25.1K | ||
| Q2 24 | $-17.2M | $-10.8K | ||
| Q1 24 | $-3.3M | — |
| Q3 24 | 50.0% | — | ||
| Q2 24 | 44.2% | 35.2% | ||
| Q1 24 | 42.4% | — |
| Q3 24 | -169957.1% | — | ||
| Q2 24 | -53453.5% | — | ||
| Q1 24 | -65278.8% | — |
| Q3 24 | -165521.4% | -120.1% | ||
| Q2 24 | -40067.4% | -23.6% | ||
| Q1 24 | -10066.7% | — |
| Q3 24 | $-0.48 | — | ||
| Q2 24 | $-0.36 | — | ||
| Q1 24 | $-0.17 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $84.7M | $47.9K |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $50.3M | $79.9K |
| Total Assets | $126.9M | $269.2K |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 24 | $84.7M | $47.9K | ||
| Q2 24 | $102.4M | $55.0K | ||
| Q1 24 | $121.4M | — |
| Q3 24 | $50.3M | $79.9K | ||
| Q2 24 | $70.8M | $94.8K | ||
| Q1 24 | $84.2M | — |
| Q3 24 | $126.9M | $269.2K | ||
| Q2 24 | $146.4M | $302.3K | ||
| Q1 24 | $163.5M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-18.0M | $-4.4K |
| Free Cash FlowOCF − Capex | $-18.3M | — |
| FCF MarginFCF / Revenue | -130371.4% | — |
| Capex IntensityCapex / Revenue | 1521.4% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 24 | $-18.0M | $-4.4K | ||
| Q2 24 | $-18.7M | $-29.6K | ||
| Q1 24 | $-11.7M | — |
| Q3 24 | $-18.3M | — | ||
| Q2 24 | $-19.0M | — | ||
| Q1 24 | $-12.8M | — |
| Q3 24 | -130371.4% | — | ||
| Q2 24 | -44179.1% | — | ||
| Q1 24 | -38697.0% | — |
| Q3 24 | 1521.4% | — | ||
| Q2 24 | 604.7% | — | ||
| Q1 24 | 3209.1% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
